Bristol Myers Squibb Canada (BMS) today announced that Canada's Drug Agency (CDA-AMC) has issued a positive reimbursement recommendation for OPDIVO® (nivolumab) in combination with YERVOY® (ipilimumab ...
Explore eight major immunology and inflammation (I&I) partnerships in 2025, from early-stage research to late-stage licensing ...
Australia is at a new frontier of property and infrastructure investment, one in which investors don’t require sweeping views ...
AI tools designed to diagnose cancer from tissue samples are quietly learning more than just disease patterns. New research ...
Pfizer Inc., AstraZeneca Plc and other companies have struck deals with the Trump administration in recent months ...
In this video, Brian T. Hill, MD, PhD, discusses data from the phase 3 EPCORE FL-1 trial, presented at the ASH Annual Meeting and Exposition.The research compared a triple drug combination therapy of ...
Harbour BioMed announced it has entered a multi-year, global strategic collaboration and license agreement with Bristol Myers ...
Chemotherapy drugs that target cancer cells without damaging normal cells remain one of the key goals of precision medicine ...
Could your lost pet post make you a scammer’s next target? Why abandoned strollers are suddenly worrying East Nashville ...
While autologous therapies are mainstream in blood cancers, experts warn against overhyping allogeneic and in vivo approaches ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback